



PRESS RELEASE

ASN Contact: Christine Feheley
(202) 640-4638 | cfeheley@asn-online.org

**EMBARGOED FOR RELEASE UNTIL
October 23, 2026 AT 4:30 PM MDT**

Phase 2 BESTOW Trial Generates Promising Kidney Function and Quality of Life Results for Tegoprubart Versus Tacrolimus Immunosuppression in Kidney Transplant Recipients

Highlights

- An analysis of BESTOW trial results indicates that kidney transplant recipients treated with tegoprubart not only have better kidney function but also have better health-related quality of life than those taking today's standard of care immunosuppressive drug tacrolimus.
- The findings will be presented at American Society of Nephrology (ASN) Kidney Week 2026 October 22–25.

Denver, CO (October 23, 2026) — The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. Kidney graft function stabilized after the first month of treatment and remained higher in tegoprubart-treated patients than in tacrolimus-treated patients at each reported time point, with a statistically significant kidney function benefit at 18 months. A recent analysis of BESTOW data found that tegoprubart also caused greater improvements in patient-reported health-related quality of life compared with tacrolimus in study participants. The findings will be presented at ASN Kidney Week 2026 October 22–25.

Of 127 treated patients, 107 (51 taking tegoprubart and 56 taking tacrolimus) completed study treatment to week 52. Health-related quality of life improvements from baseline were observed at week 52 across all 5 subscales with tegoprubart, and 4 of 5 subscales with tacrolimus. Improvements were greater with tegoprubart than tacrolimus on a mental component summary, and patients on tegoprubart also had a numerically greater reduction in total symptom score from baseline.

“Treatment today with tacrolimus helps prevent organ rejection but at a high cost to patients, with side effects such as kidney toxicity, hypertension, diabetes, tremors, and brain fog. Tegoprubart, which works by targeting the CD40L pathway that is central to how immune cells communicate, has the potential to replace tacrolimus and become the

new standard of care immunosuppression therapy across all transplant types, not just kidney transplantation,” said corresponding author Andrew Adams, MD, PhD, of the University of Minnesota Medical School. “These latest BESTOW trial results are encouraging that we may soon have a new medication that can prevent rejection without the side effects of tacrolimus and transform the broader transplant immunosuppression treatment landscape.”

Study: “Patient-Reported Outcomes in the Phase 2 BESTOW Trial Comparing Tegoprobart to Tacrolimus in Kidney Transplant Recipients”

About ASN Kidney Week

Join ASN and more than 12,000 other kidney professionals from across the globe at ASN Kidney Week 2026 in Denver, CO. The world's premier nephrology meeting, Kidney Week, provides participants with exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field. Early programs begin on October 21, followed by the Annual Meeting from October 22-25. Follow the conversation at #KidneyWk.

About ASN

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 138 countries. For more information, visit www.asn-online.org and follow us on [Facebook](#), [X](#), [LinkedIn](#), [Instagram](#), [Threads](#), and [Bluesky](#).

###